White House prepping another exec order on drug prices

President Trump is reportedly working on another executive order targeting rising drug prices, according to Reuters. The action is specifically taking aim at reducing Medicare drug prices, cutting virtually branded prescription drugs sold to the federal program, sources told Reuters.

Trump has already drafted executive orders taking rising healthcare costs into the hands of the White House. Recently, Trump was reported to be working on an order to declare a favored nations clause for drug prices, which would ensure the U.S. did not pay higher prices than other countries for medications. Another recent order requires hospitals and insurers to disclose negotiated rates for healthcare services and give patients their out-of-pocket costs before procedures.

The newest order goes much further than HHS actions to lower drug prices, which include a recent proposed rule to lower prices for Medicare Part B drugs, which are typically administered in a physician’s office.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.